<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
<channel>
<title>Desicritics Comments on Cancer Patients: Dying a Thousand Deaths</title>
<link>http://desicritics.org/</link>
<description>Superior South Asian bloggers on Culture, Media, Politics, Sport, Business, and Technology.</description>
<language>en</language>
<copyright>Copyright 2006 by the authors</copyright>
<lastBuildDate>Sun, 13 May 2007 12:36:50 EDT</lastBuildDate>
<docs>http://backend.userland.com/rss</docs>
<generator>BC custom software</generator>

<item>
<title>Comment by Aditi Nadkarni</title>
<link>http://desicritics.org/2007/05/11/004853.php#comment-180346</link>
<description>Nicely written Shantanu! I would like to add that most institutes involved in research have given priority to infectious disease, vaccine, HIV research. The funding available is largely concentrated in these areas and cancer researchers are dealt the sorry job of epidemiology which only complies statistical data but does nothing about the growing numbers. Whenever I speak of research in India, people express their gratificatino at the clinical research area having moved into the country...what they fail to realize is that pharma companies treat India like a large, poor, diseased population on whom they can then test their drugs/ formulations. This I think is not progress but rather exploitation. I do hope that things change in coming years and that biotechnology, pharmaceutical research and healthcare receives the same boost that IT received. Last I heard, was that Glaxo was planning to set up a cancer research center. Don&#039;t know if they did actually do it.    </description>
<guid isPermaLink="false">180346@desicritics.org</guid>
<pubDate>Sun, 13 May 2007 12:36:50 EDT</pubDate>
</item>

</channel>
</rss>